menu
    • menu
    [{"orgOrder":0,"company":"Sapu Bioscience","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sapu Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapu Bioscience \/ Sapu Bioscience","highestDevelopmentStatusID":"9","companyTruncated":"Sapu Bioscience \/ Sapu Bioscience"},{"orgOrder":0,"company":"Sapu Bioscience","sponsor":"Cromos Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sapu Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapu Bioscience \/ Cromos Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sapu Bioscience \/ Cromos Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Sapu Bioscience

    Menu

    Sapu Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sapu Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sapu Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen,Fluorouracil,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Cromos Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sapu BioScience and Cromos Pharma initiating P201 “ A Registrational trial for OT-101 in Pancreatic Cancer

                            Details : OT-101, is a first-in-class anti-TGF-β2 RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer (metastatic pancreatic cancer) patients. TGF-β2 has been implicated as a key contributor to the immunosuppressive landscape ...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 23, 2023

                            Lead Product(s) : Trabedersen,Fluorouracil,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Cromos Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sapu Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sapu Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Oncotelic Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer

                            Details : More than half of OT-101 (trabedersen) treated PC patients went into long term disease control (21 of 37 pts, 55%) allowing them to enter into subsequent chemotherapy which has an unexpected benefit of more than doubling their median OS, 9.3 vs. 2.6 mos,...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 12, 2022

                            Lead Product(s) : Trabedersen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Oncotelic Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth